Form 51-102F3 Material Change Report

Item 1 Name and Address of Company

Integrated Cannabis Company, Inc. (the "Company") 810 – 789 West Pender Street Vancouver, BC V6C 1H2

Item 2 Date of Material Change

February 11, 2020

Item 3 News Release

The news release was disseminated on February 11, 2020 by way of the facilities of GlobeNewswire. Copies were also forwarded to the applicable Securities Commissions via SEDAR.

Item 4 Summary of Material Change

The Company is pleased to announce that it has entered into an amending agreement (the "**Amending Agreement**") with 1200665 B.C. Ltd. (the "**TargetCo**") to settle an aggregate of \$12,500,000 in outstanding debt through the issuance of 40,322,580 common shares at the price of \$0.31 per share (the "**Debt Conversion**").

Item 5.1 Full Description of Material Change

The Company is pleased to announce that it has entered into an amending agreement (the "**Amending Agreement**") with 1200665 B.C. Ltd. (the "**TargetCo**") to settle an aggregate of \$12,500,000 in outstanding debt through the issuance of 40,322,580 common shares at the price of \$0.31 per share (the "**Debt Conversion**").

The share exchange agreement (the "**Share Exchange Agreement**") dated May 21, 2019, was previously announced on May 22, 2019 pursuant to which the Company acquired all of the issued and outstanding shares of TargetCo from the shareholders of TargetCo (the "**TargetCo Shareholders**"). The Company previously agreed to pay to the TargetCo Shareholders (the "**Earn-Out Payment**"), on a pro rata basis, \$12,500,000 subject to the terms and conditions of the Share Exchange Agreement and TargetCo completing certain milestones. The terms and conditions of the Share Exchange Agreement of when the Earn-Out Payment will be paid was amended by the Amending Agreement such that the Earn-Out Payment will be settled by common shares of the Company at \$0.31 per share for an aggregate of 40,322,580 common shares of the Company.

Item 5.2 Disclosure for Restructuring Transactions

Not applicable.

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7 Omitted Information

Not applicable.

Item 8 Executive Officer

Eugene Beukman, Director & CFO Business Telephone: 604-687-2038

Item 9 Date of Report

February 11, 2020